Letter to the Editor Regarding "The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence"

Affiliations

Comment

Barbara Finck et al. Adv Ther. 2021 Jun.

. 2021 Jun;38(6):3483-3486.

doi: 10.1007/s12325-021-01694-x. Epub 2021 Apr 29.

No abstract available

Comment on

The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence.
Feagan BG, Marabani M, Wu JJ, Faccin F, Spronk C, Castañeda-Hernández G. Feagan BG, et al. Adv Ther. 2020 Nov;37(11):4491-4518. doi: 10.1007/s12325-020-01472-1. Epub 2020 Sep 10. Adv Ther. 2020. PMID: 32910420 Free PMC article. Review.

1. Feagan BG, Marabani M, Wu JJ, Faccin F, Spronk C, Castañeda-Hernández G. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence. Adv Ther. 2020;37(11):4491–4518. doi: 10.1007/s12325-020-01472-1. - DOI - PMC - PubMed
1. Us Food And Drug Administration. Biosimilar Product Information. https://www.Fda.Gov/Drugs/Biosimilars/Biosimilar-Product-Information. Accessed 1 Dec, 2020.
1. European Medicines Agency. Biosimilar Medicines. https://www.Ema.Europa.Eu/En/Medicines/Field_Ema_Web_Categories%253aname.... Accessed 1 Dec, 2020.
1. Finck B, Tang H, Civoli F, Hodge J, O’Kelly H, Vexler V. Pharmacokinetic and pharmacodynamic equivalence of pegfilgrastim-cbqv and pegfilgrastim in healthy subjects. Adv Ther. 2020;37(10):4291–4307. - PubMed
1. Parker T, Britton L, Willis C, et al. A Retrospective analysis of the clinical and financial outcomes of converting patients from originator remicade to an infliximab biosimilar. Poster presented at: Nexus2020 Virtual; Week Of October 19, 2020.